Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer

BACKGROUND: KRAS mutations occur in 35–45% of metastatic colorectal cancers (mCRC) and preclude responsiveness to EGFR-targeted therapy with cetuximab or panitumumab. However, less than 20% patients displaying wild-type KRAS tumors achieve objective response. Alterations in other effectors downstrea...

Descripción completa

Detalles Bibliográficos
Autores principales: Sartore-Bianchi, Andrea, Di Nicolantonio, Federica, Nichelatti, Michele, Molinari, Francesca, De Dosso, Sara, Saletti, Piercarlo, Martini, Miriam, Cipani, Tiziana, Marrapese, Giovanna, Mazzucchelli, Luca, Lamba, Simona, Veronese, Silvio, Frattini, Milo, Bardelli, Alberto, Siena, Salvatore
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750753/
https://www.ncbi.nlm.nih.gov/pubmed/19806185
http://dx.doi.org/10.1371/journal.pone.0007287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750753/
https://www.ncbi.nlm.nih.gov/pubmed/19806185
http://dx.doi.org/10.1371/journal.pone.0007287

Ejemplares similares